Last reviewed · How we verify
Duloxetine hydrochloride - 60 mg
At a glance
| Generic name | Duloxetine hydrochloride - 60 mg |
|---|---|
| Also known as | LY248686, Cymbalta |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Duloxetine for Perioperative Pain in Hip Arthroplasty: A RCT (PHASE4)
- The Effect of Peppermint Oil Aromatherapy on Pain, Functional Capacity and Cost in Fibromyalgia Patients (NA)
- Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis (PHASE4)
- Duloxetine in Inflammatory Bowel Diseases (PHASE2)
- Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer (PHASE2, PHASE3)
- Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough (PHASE2)
- Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough (PHASE2)
- Home-based Transcranial Direct Current Stimulation (tDCS) Compared to Duloxetine: Non-inferiority Clinical Trial (FIBROSTIM) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Duloxetine hydrochloride - 60 mg CI brief — competitive landscape report
- Duloxetine hydrochloride - 60 mg updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI